PILOCARPINE HYDROCHLORIDE

Post-LOE

pilocarpine hydrochloride

Orasis Pharmaceuticals

ANDAOPHTHALMICSOLUTION/DROPS

Approved

Sep 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

PILOCARPINE HYDROCHLORIDE (pilocarpine hydrochloride) by Orasis Pharmaceuticals is glands. Approved for hypertension, hypertension. First approved in 2020.

Drug data last refreshed 20h ago

Mechanism of Action

glands. Pilocarpine contracts the ciliary muscle, causing increased tension on the scleral spur and opening of the trabecular meshwork spaces to facilitate outflow of aqueous humor. Outflow resistance is reduced, lowering intraocular pressure (IOP). Pilocarpine also produces miosis through…

Indications (1)

hypertension

Company

Worked on PILOCARPINE HYDROCHLORIDE at Orasis Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.